EASTON, Pa. and IRVINE, Calif., Sept. 12, 2012 /PRNewswire/ -- Easton Hospital and Masimo (NASDAQ: MASI) today jointly announce that Easton Hospital is adding a new patient monitoring system Masimo Patient SafetyNet and Masimo rainbow® Pulse CO-Oximetry technology for advanced noninvasive patient monitoring capabilities.
This conversion makes Easton Hospital the only full-service medical facility in the area equipped with Patient SafetyNet a system that helps keep patients safer by noninvasively and continuously measuring and tracking the underlying physiological conditions of up to 80 patients on four floors with Signal Extraction Pulse Oximetry. The Patient SafetyNet system, clinically shown to decrease rapid response activations by 65% and costly ICU transfers by 48%,1 detects real-time changes and abnormalities that signal declining health status. When a patient's condition deteriorates, the system automatically sends wireless alerts directly to assigned clinicians prompting a potentially lifesaving response at the patient's bedside.
In addition, clinicians at Easton Hospital will also benefit from the handheld Masimo Pronto® CO-Oximeter® for noninvasive spot-checking of total hemoglobin (SpHb®) along with SpO2, pulse rate, and perfusion index measurements without the painful needle-stick, time-consuming blood draws, and associated lab waste. Pronto is powered by Masimo rainbow® SET® technology, shown to have the highest pulse oximetry specificity (lowest rate of false alarms) and sensitivity (highest true alarm detection),2 as well as noninvasive patient monitoring solutions that allow clinicians to measure multiple blood constituents including: total hemoglobin (SpHb®).
The pulse oximetry standard-of-care at leading hospitals worldwide, Masimo rainbow® SET® provides real-time and continuous blood constituent measurements and respiration rate that enable clinicians to more rapidly assess patients and detect and treat adverse, potentially life-threatening conditions earlier.
1 Taenzer AH, Pyke JB, McGrath SP, Blike GT. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study" Anesthesiology; February 2010; Vol 112, Issue 2, pp 282-287.
2 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers".J Clin Anesth. 2012 Aug;24(5):385-91
About Easton Hospital
Easton Hospital is a 254-bed acute care teaching hospital serving more than 300,000 residents in Northampton County and the five surrounding counties in Pennsylvania and New Jersey. Founded in 1890, the Hospital offers an active Emergency Department which sees more than 35,000 annual visits; an cardiac care program including an accredited Chest Pain Center by the Society for Chest Pain Centers; a newly renovated Center for Orthopedics, Joint and Spine; a Bariatric Weight Loss program that has been designated a Center of Excellence in Bariatric Surgery; and the hospital's Easton Regional Cancer Center which is a Fox Chase Cancer Center Partner. In addition, the hospital maintains free-standing, fully-accredited residency training programs. For more information and a complete list of services, visit the hospital's website: www.easton-hospital.com.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient carehelping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic MonitoringTM, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and acquired PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care...by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using the new Masimo Pronto-7 and noninvasive sensor sizes, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.